Supplemental constraints to psilocybin pharmaceutical study, and copyright analysis generally, involve lack of information on psilocybin–drug interactions and combination-medication research [ninety nine], the lack of information about the effects of psilocybin on Mind activity/dynamics/framework and neuroplasticity [ninety nine], and the lack of